BioMed Research International

BioMed Research International / 2006 / Article
Special Issue

Neurodegenerative Diseases: Mechanisms and Therapies

View this Special Issue

Mini-Review Article | Open Access

Volume 2006 |Article ID 019365 | https://doi.org/10.1155/JBB/2006/19365

Atsushi Takeda, Takafumi Hasegawa, Michiko Matsuzaki-Kobayashi, Naoto Sugeno, Akio Kikuchi, Yasuto Itoyama, Katsutoshi Furukawa, "Mechanisms of Neuronal Death in Synucleinopathy test", BioMed Research International, vol. 2006, Article ID 019365, 4 pages, 2006. https://doi.org/10.1155/JBB/2006/19365

Mechanisms of Neuronal Death in Synucleinopathy test

Received01 Dec 2005
Accepted20 Mar 2006
Published24 May 2006

Abstract

α-synuclein is a key molecule in the pathogenesis of synucleinopathy including Parkinson's disease and multiple system atrophy. In this mini-review, we mainly focus on recent data obtained from cellular models of synucleinopathy and discuss the possible mechanisms of neurodegeneration. Recent progress suggests that the aggregate formation of α-synuclein is cytoprotective and that its precursor oligomer (protofibril) may be cytotoxic. The catechol-derived quinones are the candidate molecules that facilitate the oligomer formation of α-synuclein. Furthermore, the cellular membranes are shown to be the primary targets injured by mutant α-synucleins, and the mitochondrial dysfunction seems to be an initial step in the neuronal death.

References

  1. J L Eriksen, T M Dawson, D W Dickson, and L Petrucelli, “Caught in the act: α-synuclein is the culprit in Parkinson's disease,” Neuron, vol. 40, no. 3, pp. 453–456, 2003. View at: Google Scholar
  2. K K Dev, K Hofele, S Barbieri, V L Buchman, and H Van der Putten, “Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease,” Neuropharmacology, vol. 45, no. 1, pp. 14–44, 2003. View at: Google Scholar
  3. S Chandra, G Gallardo, R Fernandez-Chacon, O M Schluter, and T C Sudhof, “α-synuclein cooperates with CSPα in preventing neurodegeneration,” Cell, vol. 123, no. 3, pp. 383–396, 2005. View at: Google Scholar
  4. E Munoz, R Oliva, V Obach et al., “Identification of Spanish familial Parkinson's disease and screening for the Ala53Thr mutation of the α-synuclein gene in early onset patients,” Neuroscience Letters, vol. 235, no. 1-2, pp. 57–60, 1997. View at: Google Scholar
  5. R Kruger, W Kuhn, T Muller et al., “Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease,” Nature Genetics, vol. 18, no. 2, pp. 106–108, 1998. View at: Google Scholar
  6. J J Zarranz, J Alegre, J C Gomez-Esteban et al., “The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia,” Annals of Neurology, vol. 55, no. 2, pp. 164–173, 2004. View at: Google Scholar
  7. M B Feany and W W Bender, “A Drosophila model of Parkinson's disease,” Nature, vol. 404, no. 6776, pp. 394–398, 2000. View at: Google Scholar
  8. J L Eriksen, Z Wszolek, and L Petrucelli, “Molecular pathogenesis of Parkinson disease,” Archives of Neurology, vol. 62, no. 3, pp. 353–357, 2005. View at: Google Scholar
  9. M Matsuzaki, T Hasegawa, A Takeda et al., “Histochemical features of stress-induced aggregates in α-synuclein overexpressing cells,” Brain Research, vol. 1004, no. 1-2, pp. 83–90, 2004. View at: Google Scholar
  10. T Hasegawa, M Matsuzaki, A Takeda et al., “Accelerated α-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells,” Brain Research, vol. 1013, no. 1, pp. 51–59, 2004. View at: Google Scholar
  11. B I Giasson, J E Duda, I V Murray et al., “Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions,” Science, vol. 290, no. 5493, pp. 985–989, 2000. View at: Google Scholar
  12. S R Paik, H J Shin, and J H Lee, “Metal-catalyzed oxidation of α-synuclein in the presence of Copper(II) and hydrogen peroxide,” Archives of Biochemistry and Biophysics, vol. 378, no. 2, pp. 269–277, 2000. View at: Google Scholar
  13. E Paxinou, Q Chen, M Weisse et al., “Induction of α-synuclein aggregation by intracellular nitrative insult,” The Journal of Neuroscience, vol. 21, no. 20, pp. 8053–8061, 2001. View at: Google Scholar
  14. V N Uversky, J Li, and A L Fink, “Evidence for a partially folded intermediate in α-synuclein fibril formation,” The Journal of Biological Chemistry, vol. 276, no. 14, pp. 10737–10744, 2001. View at: Google Scholar
  15. A Kikuchi, A Takeda, and H Onodera, “Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy,” Neurobiology of Disease, vol. 9, no. 2, pp. 244–248, 2002. View at: Google Scholar
  16. J A Johnston, C L Ward, and R R Kopito, “Aggresomes: a cellular response to misfolded proteins,” The Journal of Cell Biology, vol. 143, no. 7, pp. 1883–1898, 1998. View at: Google Scholar
  17. M Tanaka, Y M Kim, G Lee, E Junn, T Iwatsubo, and M M Mouradian, “Aggresomes formed by α-synuclein and synphilin-1 are cytoprotective,” The Journal of Biological Chemistry, vol. 279, no. 6, pp. 4625–4631, 2004. View at: Google Scholar
  18. M Arrasate, S Mitra, E S Schweitzer, M R Segal, and S Finkbeiner, “Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death,” Nature, vol. 431, no. 7010, pp. 805–810, 2004. View at: Google Scholar
  19. M Matsuzaki-Kobayashi, T Hasegawa, A Kikuchi, A Takeda, and Y Itoyama, “Role of iron in the intracellular aggregation of α-synuclein,” Movement Disorders, vol. 19, no. sup9, p. S36, 2004. View at: Google Scholar
  20. H G Lee, R B Petersen, X Zhu et al., “Will preventing protein aggregates live up to its promise as prophylaxis against neurodegenerative diseases?,” Brain Pathology, vol. 13, no. 4, pp. 630–638, 2003. View at: Google Scholar
  21. S Ueda, S Sakakibara, E Watanabe, K Yoshimoto, and N Koibuchi, “Vulnerability of monoaminergic neurons in the brainstem of the zitter rat in oxidative stress,” Progress in Brain Research, vol. 136, pp. 293–302, 2002. View at: Google Scholar
  22. A H Stokes, T G Hastings, and K E Vrana, “Cytotoxic and genotoxic potential of dopamine,” Journal of Neuroscience Research, vol. 55, no. 6, pp. 659–665, 1999. View at: Google Scholar
  23. J L Bolton, M A Trush, T M Penning, G Dryhurst, and T J Monks, “Role of quinones in toxicology,” Chemical Research in Toxicology, vol. 13, no. 3, pp. 135–160, 2000. View at: Google Scholar
  24. R G Perez, J C Waymire, E Lin, J J Liu, F Guo, and M J Zigmond, “A role for α-synuclein in the regulation of dopamine biosynthesis,” The Journal of Neuroscience, vol. 22, no. 8, pp. 3090–3099, 2002. View at: Google Scholar
  25. F J Lee, F Liu, Z B Pristupa, and H B Niznik, “Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis,” FASEB Journal, vol. 15, no. 6, pp. 916–926, 2001. View at: Google Scholar
  26. R G Perez and T G Hastings, “Could a loss of α-synuclein function put dopaminergic neurons at risk?,” Journal of Neurochemistry, vol. 89, no. 6, pp. 1318–1324, 2004. View at: Google Scholar
  27. A Sidhu, C Wersinger, and P Vernier, “α-synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease,” FEBS Letters, vol. 565, no. 1–3, pp. 1–5, 2004. View at: Google Scholar
  28. K A Conway, J C Rochet, R M Bieganski, and P T Jr Lansbury, “Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct,” Science, vol. 294, no. 5545, pp. 1346–1349, 2001. View at: Google Scholar
  29. H T Li, D H Lin, X Y Luo et al., “Inhibition of α-synuclein fibrillization by dopamine analogs via reaction with the amino groups of α-synuclein: implication for dopaminergic neurodegeneration,” FEBS Journal, vol. 272, no. 14, pp. 3661–3672, 2005. View at: Google Scholar
  30. A Takeda, Y Tomita, S Okinaga, H Tagami, and S Shibahara, “Functional analysis of the cDNA encoding human tyrosinase precursor,” Biochemical and Biophysical Research Communications, vol. 162, no. 3, pp. 984–990, 1989. View at: Google Scholar
  31. T Hasegawa, M Matsuzaki, A Takeda et al., “Increased dopamine and its metabolites in SH-SY5Y neuroblastoma cells that express tyrosinase,” Journal of Neurochemistry, vol. 87, no. 2, pp. 470–475, 2003. View at: Google Scholar
  32. T Hasegawa, M Matsuzaki-Kobayashi, A Takeda et al., “Synergistic interaction between α-synuclein and oxidized catechol metabolites produced by tyrosinase: implications for selective neurodegeneration in Parkinson's disease,” FEBS Letters, vol. 580, pp. 2147–2152, 2006. View at: Google Scholar
  33. H A Lashuel, D Hartley, B M Petre, T Walz, and P T Jr Lansbury, “Neurodegenerative disease: amyloid pores from pathogenic mutations,” Nature, vol. 418, no. 6895, p. 291, 2002. View at: Google Scholar
  34. M J Volles and P T Jr Lansbury, “Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism,” Biochemistry, vol. 41, no. 14, pp. 4595–4602, 2002. View at: Google Scholar
  35. R Kayed, Y Sokolov, B Edmonds et al., “Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases,” The Journal of Biological Chemistry, vol. 279, no. 45, pp. 46363–46366, 2004. View at: Google Scholar
  36. M R Gluck and G D Zeevalk, “Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases,” Journal of Neurochemistry, vol. 91, no. 4, pp. 788–795, 2004. View at: Google Scholar
  37. K Furukawa, M Matsuzaki-Kobayashi, T Hasegawa et al., “High ion permeability of plasma membrane caused by the α-synuclein mutations contributes to cellular degeneration,” Journal of Neurochemistry, vol. 97, pp. 1071–1077, 2006. View at: Google Scholar
  38. M P Mattson and S L Chan, “Dysregulation of cellular calcium homeostasis in Alzheimer's disease: bad genes and bad habits,” Journal of Molecular Neuroscience, vol. 17, no. 2, pp. 205–224, 2001. View at: Google Scholar
  39. K Furukawa, Y Wang, P J Yao et al., “Alteration in calcium channel properties is responsible for the neurotoxic action of a familial frontotemporal dementia tau mutation,” Journal of Neurochemistry, vol. 87, no. 2, pp. 427–436, 2003. View at: Google Scholar

Copyright © 2006 Atsushi Takeda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views142
Downloads418
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.